Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
72
resultados
Última actualización
17/04/2026 [06:45:00]
Resultados 25 a 50 de 72
Resumen de: EP4721737A1
Use of a pharmaceutical composition comprising a new compound comprising diazanylidenesulfonyl structure in the preparation of a medicament for treating anemia-related disease. The anemia-related disease can involve myelodysplastic syndrome (MDS), hemoglobinopathy, sickle cell anemia (SCD), β-thalassemia, hereditary non-spherocytic hemolytic anemia, hemolytic anemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, congenital anemia or anemia of chronic disease.
Resumen de: EP4721734A1
0001 The use of mitoxantrone liposome combined with cytarabine, or further combined with other drugs, such as homoharringtonine or venetoclax, in the preparation of drugs used for treating acute myeloid leukemia (AML). Provided is a method of treating AML, the method comprising administering to an AML patient a pharmaceutical composition comprising mitoxantrone liposome and cytarabine, wherein the pharmaceutical composition may also comprise homoharringtonine or venetoclax.
Resumen de: AU2024341370A1
The present disclosure provides SOS-1 inhibitors, such as bicyclic compounds or macrocyclic compounds, alone or in combination with TKI - resitant to BCR-ABL tyrosine kinase, such as dasatinib or imatinib, for use in the treatment of philadelphia chromosome positive (Ph+) blood cancer, such as CML (chronic myelogenous leukemia, also named chronic myeloid leukemia), Ph+ALL (acute lymphoblastic leukemia) and Ph+AML (acute lymphoblastic lymphoma).
Resumen de: US20260092085A1
A novel peptide nucleic acid (PNA) oligomer capable of forming a PNA/RNA/PNA triplex when binding to its target RNA is described. An anti-micro RNA (miRNA) capable of binding miR-155 was designed based on the novel PNA oligomer and was shown to significantly decrease miR-155 expression in vitro in lymphoma cell lines. In vivo testing in xenograft mouse models resulted in reduced miR-155 expression followed by reduced tumor growth. Methods of making and using the novel PNA oligomer for targeting other coding and noncoding RNAs are described.
Resumen de: WO2026067824A1
The present invention belongs to the technical field of stem cells. Provided are a culture medium for induced hypoblast stem cells and the use thereof. Provided is a culture medium for induced hypoblast stem cells. The components of the culture medium comprise platelet-derived growth factor AA, a leukemia inhibitory factor, fibroblast growth factor 4, GSK-3α/β inhibitor CHIR99021, TGF-β type I receptor inhibitor A83-01, and bone morphogenetic protein 4. The culture medium for induced hypoblast stem cells can accurately regulate the activity of key signaling pathways such as NODAL, BMP, WNT, FGF, and JAK/STAT in the process of somatic cell reprogramming, and ensure that the properties of hypoblast stem cells are maintained in the process of somatic cell reprogramming to support the self-renewal and hypoblast lineage induction of somatic cells in the reprogramming process, thereby realizing the fate transition of somatic cells to hypoblast stem cells.
Resumen de: US20260092097A1
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
Resumen de: WO2026068605A1
The present disclosure provides methods of predicting whether a subject is at risk of developing resistance to a treatment for chronic myelogenous leukaemia (CML) and/or progressing to blast crisis phase, wherein the subject has CML or has been diagnosed with CML. The present disclosure also provides methods of selecting a subject for treatment with a given therapy, wherein the subject has chronic myelogenous leukaemia (CML) or has been diagnosed with CML. The present disclosure also provides kits useful for performing said methods.
Resumen de: WO2026072967A1
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: WO2026072888A1
Cell surface polypeptides SEMA-4A and FCRL3 have been identified as being associated with multiple myeloma. Accordingly, these peptides represent targets for immuno-based therapeutic strategies for treating multiple myeloma. Antibodies that specifically binds to one of these polypeptides can be used to treat multiple myeloma. Accordingly, new compositions and methods utilizing novel antibodies that target SEMA-4A and FCRL3 are described.
Resumen de: WO2026072990A1
The present disclosure relates to methods of treating T-cell large granular lymphocytic leukemia (T-LGLL) with antibodies, or antigen-binding fragments thereof, that specifically bind to killer cell lectin-like receptor G1 (KLRG1), and methods for maintaining remission of T-cell large granular lymphocytic leukemia in a patient.
Resumen de: AU2024390850A1
Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.
Resumen de: WO2026069350A2
An Umbilical cord derived mesenchymal stem cell (UC-MSC) conditioned media (UC- MSC-CM) composition of the range from 5%-100% possessing immunomodulatory effect inhibiting tumour growth when administered intraperitoneally and intravenously. MSC- CM arrests cell cycle in leukaemia cells (K-562 and HL-60), lung cancer cells (A549 and HOP-62), breast cancer cells (MDA-MB-231 and MCF-7) and cervical cancer cells (HeLa). Elevated levels of IL-6, TIM3 and TIMP2 in MSC-CM confer to its immunomodulatory function by leading to an increase in expression of activation markers, cytotoxic granules, mucosal associated invariant T cells and decreasing the inflammasome pathway activation, consequently decreasing the levels of innate immune inflammasome pathway molecules in treated xenograft tumor tissues. MSC-CM as an adjunct with IL-12 augments cytotoxic potential against cancer cell lines. Tumor inhibition effect of MSC-CM is shown by significant reduction of relative tumor volume which is expressed by fold change of genes involved in various pathways affecting xenograft tumor growth.
Resumen de: AU2024360739A1
The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.
Resumen de: US20260083673A1
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).
Resumen de: US20260083844A1
Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. As disclosed herein, anti-inflammatory macrophages suppress CAR-T cell expansion, induce death, and reduce CAR expression. Disclosed is a method for enhancing anti-tumor efficacy of immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject a nitric oxide synthase (NOS) inhibitor.
Resumen de: US20260085073A1
The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein I (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.
Resumen de: US20260083707A1
There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
Resumen de: US20260085064A1
The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structuralor a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
Resumen de: WO2026064696A1
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating MDS, and related syndromes/conditions/symptoms thereof.
Resumen de: WO2026060534A1
Disclosed are methods of reducing the risk of a subject developing hematologic malignancies and myelodysplastic syndrome, the methods comprising administering an effective amount of colchicine to the subject, wherein the subject has been determined to have a clonal hematopoiesis mutation.
Resumen de: WO2026063424A1
The present invention provides a method and the like for predicting prognosis of multiple myeloma using, as a novel biomarker, IL5RA of extracellular vesicles derived from a biological sample of a subject.
Resumen de: US20260083749A1
Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and/or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and/or to achieve complete remissions in patients with AML, including those with poor prognostic markers.
Resumen de: US20260085082A1
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
Resumen de: EP4714975A1
The present disclosure provides an antibody capable of binding to LILRB4 and a bispecific antibody capable of binding to LILRB4 and CD3. Further provided are a nucleic acid molecule encoding the antibodies, an expression vector for use in expressing the antibodies, a host cell, and a method. The present disclosure also relates to a method for treating a solid tumor, multiple myeloma, or leukemia such as acute myeloid leukemia (AML) using the anti-LILRB4×CD3 bispecific antibody of the present disclosure.
Nº publicación: US20260078348A1 19/03/2026
Solicitante:
XILIS INC [US]
Xilis, Inc
Resumen de: US20260078348A1
MicroOrganoSpheres (MOS) generated using cells from multiple myeloma bone marrow biopsies are provided herein, as are methods and materials for making and using such MOS.
BOPI
Sede Electrónica
